Events

Oncoinvent AS, will participate in a virtual panel discussion at the JonesTrading Virtual Radiopharma Day on Tuesday, October 29, 2024 at 2:35 p.m. ET.

Virtual

Dr Yun Wang, principal investigator in the RAD-18-001 study in ovarian cancer, will  present at the Norwegian Radium Hospital and Memorial Sloan Kettering Meeting “Updates and Controversies in Gynecological Oncology”.

In the lecture titled “Novel radiopharmaceutical for peritoneal recurrence in ovarian cancer”, safety data from the dose escalation cohort when all patients had completed at least 12 months follow up, will be presented.

The auditorium in Building K
Institute for Cancer Research,
The Norwegian Radium Hospital
Oslo, Norway

CEO, Anders Månsson will present Oncoinvent at the Cantor Fitzgerald Frontiers Radiopharma Virtual Summit

Virtual

Members of management will present at the Evercore ISI 2024 Emerging Biotech Conference on Wednesday, February 28, 2024 at 11:20 a.m. ET.

Virtual

CEO, Anders Månsson and CFO, Tore Kvam will present Oncoinvent to investors during the JP Morgan 42nd Annual Healthcare Conference

San Francisco

CEO, Anders Månsson will present Oncoinvent at the DNB Nordic Healthcare Conference 2023

Dronning Eufemias gate 30, Oslo, Norway

Oncoinvent will be presenting the company at the Nordic American Healthcare Conference 2023. The company will be represented by CEO Anders Månsson and CFO Tore Kvam

Shearman & Sterling, 599 Lexington Ave, New York City

CEO, Anders Månsson will be at the Nordic Life Science Days in Copenhagen

Bella Center – Copenhagen

Oncoinvent would like to extend an invitation to a short update on the company and a presentation on Q3 report including outlook. The presentation will be held on Thursday 23. November 2023 at 10:00 AM in the offices of Carnegie, Fjordalléen 16, Oslo, 5. floor, Meeting room: Verftet. It will also be possible to attend virtually.

To attend, please register with ir@oncoinvent.com. Logon details will be distributed to registered attendees.

Oncoinvent ønsker med dette å invitere til en kort status oppdatering og presentasjon av 3. kvartal inkludert veien videre. Presentasjonen vil holdes torsdag 23. november 2023, kl. 10:00 i lokalene til Carnegie, Fjordalléen 16, Oslo, 5. Etasje, Møterom: Verftet Det vil også være mulig å delta virtuelt.

Vi ber om at deltakere registrerer seg ved å sende en e-post til ir@oncoinvent.com. Eventuelle påloggingsdetaljer vil distribueres deretter.

Carnegie, Fjordalléen 16, Oslo, 5. floor,
Meeting room: Verftet.

Oncoinvent will be attending Bio-Europe in Munich November 6th to 8th and have meetings with investors.

Oncoinvent will present the company at the Hadean Ventures annual showcase.

Oslo, Norway

CEO, Anders Månsson and CFO, Tore Kvam presented Oncoinvent at the Radforsk’s podcast Radium episode 284. The podcast can be heard HERE (norwegian)

Virtual

CEO, Anders Månsson presentes Oncoinvent at the LSX conference and meet with investors.

Bella Sky, Center Blvd. 5, 2300 Copenhagen Denmark

Oncoinvent will present at the 13th PSOGI Congress:

CMO, Kari Myren will present at the poster session: Title: “Novel radiopharmaceutical for intraperitoneal treatment of peritoneal metastasis from colorectal and ovarian cancer after complete surgical resection”,

Dr. Stein Gunnar Larsen, Oslo University Hospital will also present an oral abstract: Title: “18-month safety and efficacy after intraperitoneal treatment with 224Radium-labelled microparticles (Radspherin) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for colorectal peritoneal metastasis (PM)”

October 4th-6th, 2023, Venice, Italy

Anders Månsson recently visited BioStock Studio to talk about his new role as CEO of Oncoinvent. The full interview is available at: Interview with Anders Månsson

Virtual

Senior management of Oncoinvent will be participating in a virtual fireside chat with biotech analyst Nicole Germino at Truist Securities

Virtual – HERE

Oncoinvent be represented by CMO, Dr. Kari Myren at the 2023 ESGO congress.

There will also be a mini oral presentation on the theme “First Experience With Intra-Abdominal 224Radium-Labelled Microparticles (Radspherin) After Cytoreductive Surgery For Peritoneal Metastasis In Recurrent Epithelial Ovarian Cancer (Phase 1 Study)” by Dr. Els Van Nieuwenhuysen, University Hospital Leuven, Leuven, Belgium

The congress venue is situated at the Istanbul Congress Center (ICC), Türkiye

Oncoinvent will be at the EANM conference in Vienna from September 9th – 13th

Vienna

Oncoinvent will participate in a virtual fireside chat at the TD Cowen Radiopharmaceutical Innovation Summit on Tuesday, June 20, 2023, at 9:30 a.m. ET.

Virtual

CEO, Jan Alfheim will present Oncoinvent at the Guggenheim Radiopharmaceuticals Day conference and have 1×1 meetings with investors togheter with CFO, Tore Kvam

Convene, 101 Park Avenue, New York

Oncoinvent would like to extend an invitation to a short update on the company. The presentation will be held on Friday 17. February 2023 at 09:00 AM in the company offices at Gullhaugsveien 7, Oslo, 3rd Floor. It will also be possible to attend virtually.

To attend, please register with kvam@oncoinvent.com.

————————————————–

Oncoinvent ønsker med dette å invitere til en kort status oppdatering. Presentasjonen vil holdes Fredag 17. februar 2023, kl. 09:00 i selskapets lokaler i Gullhaugsveien 7, Oslo, 3. etasje. Det vil også være mulig å delta virtuelt.

Vi ber om at deltakere registrerer seg ved å sende en e-post til kvam@oncoinvent.com.

Gullhaugveien 7, Oslo / Virtual

CEO, Jan Alfheim will be presenting Oncoinvent at the virtual B. Riley Securities’ 3rd Annual Oncology Conference on Wednesday 18th of January 2023 at 19:00 CET (01:00 PM ET). For more info please see https://brileyoncology22.sequireevents.com/.

Oncoinvent AS, a clinical stage radiopharmaceutical company, announces that its CEO, Jan A. Alfheim will present the company at DNB’s 13th annual Nordic Healthcare Conference 2022 on 15th of December 2022. The presentation will take place from 09:50-10:10 CET in the Market Session Room C2.

CEO of Oncoinvent, Jan A. Alfheim, will be presenting the company at the 4th Targeted Radiopharmaceuticals Europe December 7 at 14:30

Leonardo Royal Amsterdam
Paul van Vlissingenstraat 24
1096 BK
Amsterdam
Netherlands

CFO of Oncoinvent, Tore Kvam, will be presenting the company at Carnegie Nordic Life Science Champions Seminar December 7 at 14:30

Virtual

CEO of Oncoinvent, Jan A. Alfheim, will be presenting the company at ABGSC Norwegian Oncology Seminar November 23 at 12:50

ABG Sundal Collier
Ruseløkkveien 26, 8th floor.
Oslo

The aim of this study was to estimate the absorbed doses to normal tissues for patients injected intraperitoneally with a suspension of radium-224 adsorbed in calcium carbonate microparticles (224Ra-CaCO3-MP) for treating peritoneal carcinomatosis originating from colorectal cancer.

CCIB – Centre de Convencions Internacional
de Barcelona / Barcelona International
Convention Centre
Hall 111

e-Poster Presentation Session 11 – Dosimetry

Committee: Dosimetry – Novel Tracers and Computer-Based Modelling

CEO, Jan A. Alfheim, will be speaking at the LSX Nordic Biotech Congress and host 1-on-1 meetings with investors on 6-7 September, 2022

Bella Sky, Center Blvd. 5, 2300 Copenhagen, Denmark

Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor.

To attend, please register with kvam@oncoinvent.com.

Oncoinvent ønsker med dette å invitere til presentasjon av resultater for 1. kvartal 2022. Presentasjonen vil holdes onsdag 1. juni 2022, kl. 08:30 i selskapets lokaler i Gullhaugsveien 7, Oslo, 3. etasje.

Vi ber om at deltakere registrerer seg ved å sende en e-post til kvam@oncoinvent.com.

Gullhaugsveien 7, Oslo, 3rd Floor.

CEO, Jan A. Alfheim, will present Oncoinvent at the DNB Small & Medium Enterprises Conference and host 1-on-1 meetings with investors on April 7, 2022

Dronning Eufemias gate 30, Oslo, Norway

Company management will participate in 1×1 meetings

Oncoinvent will participate in fireside chat in the B. Riley Radiation Oncology Investor Day

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, announces that its CEO, Jan A. Alfheim will present the company at a live webcast at DNB’s 12^th Nordic Healthcare Conference on 16 December 2021. The presentation will take place from 10:45-11:05 CET.

Oncoinvent would like to extend an invitation to a presentation of the Q3 2021 results. The presentation will be held virtually via Teams at 09:00 on Friday 12. November 2021.

We request that participants register with kvam@oncoinvent.com for logon details.

Virtual on Teams

Oncoinvent to present four posters at the 34^th Annual Congress of the European Association of Nuclear Medicine

Virtual

Oncoinvent would like to extend an invitation to a presentation of the Q2 2021 results. The presentation will be held virtually via Teams at 09:00 on Thursday 9. September 2021.

We request that participants register with kvam@oncoinvent.com for logon details.

Virtual

Virtual Event organized by Stern IR at time of J.P. Morgan 2021 Health Conference: January 11-14, 2021

Oncoinvent CEO, Jan A. Alfheim will present the company at Stern IR’s  event that is scheduled to occur during the virtual J.P. Morgan Healthcare Conference . The presentation is awailable at https://wsw.com/webcast/sternir/oncoi/2294600.

Virtual

Oncoinvent would like to extend an invitation to a presentation of the Q3 2020 results. The presentation will be held virtually at 10:00 on Friday 23. October 2020. We request that participants register with kvam@oncoinvent.com for logon details.

The quarterly report will be made available on www.oncoinvent.com on the 23. October 2020.

Virtual

Oncoinvent will present the e-poster “Size-controlled ²²⁴Ra-labelled calcium carbonate microparticles against peritoneal carcinomatosis” at the virtual 33rd annual European Association of Nuclear Medicine (EANM) Congress. The abstract (no. EP-290) can be downloaded here.

Virtual

Oncoinvent CEO, Jan A. Alfheim will present the company at the virtual Nordic American Life Science Conference.

Virtual

Oncoinvent CEO, Jan A. Alfheim presented the company at the virtual Hadean Ventures Annual Event 2020. The presentation is available here (https://www.youtube.com/watch?v=f_cJUHC4vSg&feature=emb_logo).

Virtual

Oncoinvent CEO, Jan A. Alfheim will present the company at the DnB Nordic Healthcare Conference 2019 at the venture session for scaleups.

Audioturium 1

Dronning Eufemias gate 30,

Oslo, Norway

Oncoinvent CEO, Jan A. Alfheim will present the company at the Nordic American Life Science Conference in New York, USA 

Well Said, Convene, 151 West 42nd Street, New York, NY 10036

Oncoinvent would like to extend an invitation to a presentation of the Q3 2019 results. The presentation will be held at 14:00 on Thursday 31. October 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.

To attend, please register with 

kvam@oncoinvent.com

The quarterly report will be made available on www.oncoinvent.com on the 31. October 2019

Gullhaugsveien 7, Oslo

Head of Clinical Operations at Oncoinvent, Helen Johansen Blanco will be presenting at the conference “Outsourcing in Clinical Trials and Clinical Trial Supply Nordics”.

Scandic Copenhagen, Denmark

CSO Tina Bønsdorff, presented the ePoster «Feasibility of Ra-224 SPECT CT imaging in a therapeutic setting – a phantom study» developed by Stokke (PhD, Assoc. Prof) and Mikalsen (PhD) at Oslo University Hospital, Oslo, NORWAY, at the European Association of Nuclear Medicine (EANM) annual conference held in Barcelona.

CCIB – Centre de Convencions Internacional de Barcelona,
Placa de Willy Brandt, 11-14
08019 Barcelona, Spain

Oncoinvent would like to extend an invitation to a presentation of the Q2 2019 results. The presentation will be held at 15:00 on Thursday 29. August 2019 in the company offices at Gullhaugsveien 7, Oslo, 2nd Floor.

Going forward quarterly result presentations will be held on a regular basis.

To attend, please register with
kvam@oncoinvent.com

The quarterly report will be made available on www.oncoinvent.com on the 29. August 2019

Gullhaugsveien 7, Oslo

Oncoinvent researcher Elisa Napoli will present the poster “A primary activity standard for the alpha-emitting radionuclide Ra-224” at the SNMMI 2019 Annual Meeting.

SNMMI 2019 Annual Meeting, Anaheim, CA

Jan A. Alfheim, CEO of Oncoinvent will give a short status presentation about the company at the ABG Sundal Collier’s Norwegian Biotech Oncology Seminar

ABG Sundal Collier, Munkedamsveien 45E, 7th floor, Oslo, Norway

Oncoinvent CEO Jan A. Alfheim will be presenting the company during the International Cancer Cluster Showcase at the BIO International Convention 2019.

BIO International, Pennsylvania Convention Center, Room : 204B, level 200, 1101 Arch St, Philadelphia, PA 10107, USA

Oncoinvent CEO Jan A. Alfheim will be presenting at 10:25 during the morning Venture Session on Thursday the 14th of December

DNB Bank, Dronning Eufemias Gate 30, Bjørvika, 0191 Oslo, Norway

The poster ‘Preclinical Evaluation of a Novel Alpha-Particle Emitting Therapeutic Agent for Intraperitoneal Therapy of Peritoneal Metastases’ by Oncoinvent scientists Tina B. Bønsdorff, Sara Westrøm, Øyvind S. Bruland and Roy H. Larsen will be presented at the congress.

Austria Center Vienna, Bruno Kreisky Platz 1, Vienna, 1210 Austria

Researchers Sara Westrøm and Elisa Napoli will each be presenting findings of their research during the morning session on Sunday the 22nd of October

Austria Center Vienna, Bruno Kreisky Platz 1,Vienna, 1210 Austria

Oncoinvent CEO Jan A. Alfheim speaks with Radforsk’s Jónas Einarsson and Elisabeth Kirkeng Andersen

Ullernchausséen 64 – 66, 0379 Oslo, Norway

CEO Jan A. Alfheim will give a company presentation at the upcoming Partnership4Life symposium on February 15.

Forskningsparken, Gaustadaléen 21 Oslo, Norge

DNB BANK, Dronning Eufemiasgate 30, Bjørvika, NO- 0191 Oslo